Triple-negative breast cancer and PTEN (phosphatase and tensin homologue)loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer

Breast Cancer Research

Volumn 14, Issue 6, 2012, Pages

  Phuah, Sze Yee ^a   Looi, Lai Meng ^b   Hassan, Norhashimah ^a,b   Rhodes, Anthony ^b,c   Dean, Sarah ^c   Taib, Nur A M ^b   Yip, Cheng Har ^b   Teo, Soo Hwang ^a,b  

^a CANCER RESEARCH INITIATIVES FOUNDATION   (Malaysia)

^b UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

^c UNIVERSITY OF THE WEST OF ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN; PTEN PROTEIN, HUMAN;

ADULT; ARTICLE; BREAST CANCER; CANCER PATIENT; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EARLY CANCER; EPIDEMIOLOGY; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; GENE EXPRESSION; GENE LOSS; GENE MUTATION; GERMLINE MUTATION; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALAYSIA; MANCHESTER SCORING; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; PREDICTIVE VALUE; PREVALENCE; RISK FACTOR; SANGER SEQUENCING; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; TRIPLE NEGATIVE BREAST CANCER; BREAST TUMOR; DNA SEQUENCE; GENETIC SCREENING; GENETICS; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; ONSET AGE; PATHOLOGY; TRIPLE NEGATIVE BREAST NEOPLASMS;

ADULT; AGE OF ONSET; BASE SEQUENCE; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; GENETIC TESTING; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; MUTATION; PTEN PHOSPHOHYDROLASE; RECEPTORS, ESTROGEN; SEQUENCE ANALYSIS, DNA; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84868217990     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3347     Document Type: Article

References (28)

1. Rehman FL, Lord CJ, Ashworth A. Synthetic lethal approaches to breast cancer therapy. Nat Rev Clin Oncol 2010, 7:718-724. 10.1038/nrclinonc.2010.172, 20956981.
2. Kurian AW. BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications. Curr Opin Obstet Gynecol 2010, 22:72-78. 10.1097/GCO.0b013e328332dca3, 19841585.
3. Young SR, Pilarski RT, Donenberg T, Shapiro C, Hammond LS, Miller J, Brooks KA, Cohen S, Tenenholz B, Desai D, Zandvakili I, Royer R, Li S, Narod SA. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer 2009, 9:86. 10.1186/1471-2407-9-86, 2666759, 19298662.
4. Chang J, Hilsenbeck SG, Sng JH, Wong J, Ragu GC. Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients. Clin Cancer Res 2001, 7:1739-1742.
5. Kwon JS, Gutierrez-Barrera AM, Young D, Sun CC, Daniels MS, Lu KH, Arun B. Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol 2010, 28:4214-4220. 10.1200/JCO.2010.28.0719, 20733129.
6. Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, Trudel M, Akslen LA. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003, 95:1482-1485. 10.1093/jnci/djg050, 14519755.
7. Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, Bishop T, Benitez J, Rivas C, Bignon YJ, Chang-Claude J, Hamann U, Cornelisse CJ, Devilee P, Beckmann MW, Nestle-Krämling C, Daly PA, Haites N, Varley J, Lalloo F, Evans G, Maugard C, Meijers-Heijboer H, Klijn JG, Olah E, Gusterson BA, Pilotti S, Radice P, Scherneck S, Sobol H, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005, 11:5175-5180. 10.1158/1078-0432.CCR-04-2424, 16033833.
8. Saal LH, Gruvberger-Saal SK, Persson C, Lövgren K, Jumppanen M, Staaf J, Jönsson G, Pires MM, Maurer M, Holm K, Koujak S, Subramaniyam S, Vallon-Christersson J, Olsson H, Su T, Memeo L, Ludwig T, Ethier SP, Krogh M, Szabolcs M, Murty VV, Isola J, Hibshoosh H, Parsons R, Borg A. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet 2008, 40:102-107. 10.1038/ng.2007.39, 3018354, 18066063.
9. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
10. Bayraktar S, Gutierrez-Barrera AM, Liu D, Tasbas T, Akar U, Litton JK, Lin E, Albarracin CT, Meric-Bernstam F, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat 2011, 130:145-153. 10.1007/s10549-011-1711-z, 21830012.
11. Evans DG, Howell A, Ward D, Lalloo F, Jones JL, Eccles DM. Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer. J Med Genet 2011, 48:520-522. 10.1136/jmedgenet-2011-100006, 21653198.
12. Thirthagiri E, Lee SY, Kang P, Lee DS, Toh GT, Selamat S, Yoon SY, Taib NA, Thong MK, Yip CH, Teo SH. Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer. Breast Cancer Res 2008, 10:R59. 10.1186/bcr2118, 2575532, 18627636.
13. Toh GT, Kang P, Lee SS, Lee DS, Lee SY, Selamat S, Mohd Taib NA, Yoon SY, Yip CH, Teo SH. BRCA1 and BRCA2 germline mutations in Malaysian women with early-onset breast cancer without a family history. PLoS One 2008, 3:e2024. 10.1371/journal.pone.0002024, 2295262, 18431501.
14. Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, Farid LM, Venter D, Antoniou A, Storfer-Isser A, Smyth E, Steel CM, Haites N, Scott RJ, Goldgar D, Neuhausen S, Daly PA, Ormiston W, McManus R, Scherneck S, Ponder BA, Ford D, Peto J, Stoppa-Lyonnet D, Bignon YJ, Struewing JP, Spurr NK, Bishop DT, Klijn JG, Devilee P, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998, 90:1138-1145. 10.1093/jnci/90.15.1138, 9701363.
15. Apicella C, Andrews L, Hodgson SV, Fisher SA, Lewis CM, Solomon E, Tucker K, Friedlander M, Bankier A, Southey MC, Venter DJ, Hopper JL. Log odds of carrying an Ancestral Mutation in BRCA1 or BRCA2 for a Defined personal and family history in an Ashkenazi Jewish woman (LAMBDA). Breast Cancer Res 2003, 5:R206-216. 10.1186/bcr644, 314405, 14580256.
16. Evans DG, Lalloo F, Wallace A, Rahman N. Update on the Manchester Scoring System for BRCA1 and BRCA2 testing. J Med Genet 2005, 42:e39. 10.1136/jmg.2005.031989, 1736089, 15994864.
17. Mavaddat N, Rebbeck TR, Lakhani SR, Easton DF, Antoniou AC. Incorporating tumour pathology information into breast cancer risk prediction algorithms. Breast Cancer Res 2010, 12:R28. 10.1186/bcr2576, 2917017, 20482762.
18. Evans DG, Lalloo F, Cramer A, Jones EA, Knox F, Amir E, Howell A. Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing. J Med Genet 2009, 46:811-817. 10.1136/jmg.2009.067850, 19542080.
19. James PA, Doherty R, Harris M, Mukesh BN, Milner A, Young MA, Scott C. Optimal selection of individuals for BRCA mutation testing: a comparison of available methods. J Clin Oncol 2006, 24:707-715. 10.1200/JCO.2005.01.9737, 16446345.
20. Haffty BG, Silber A, Matloff E, Chung J, Lannin D. Racial differences in the incidence of BRCA1 and BRCA2 mutations in a cohort of early onset breast cancer patients: African American compared to white women. J Med Genet 2006, 43:133-137. 2564628, 15983021.
21. Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 2008, 26:4282-4288. 10.1200/JCO.2008.16.6231, 18779615.
22. Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury JS, Stemke-Hale K, Hennessy BT, Arun BK, Hortobagyi GN, Do KA, Mills GB, Meric-Bernstam F. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 2011, 17:1082-1089. 10.1158/1078-0432.CCR-10-2560, 3048924, 21233401.
23. Comen E, Davids M, Kirchhoff T, Hudis C, Offit K, Robson M. Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi women. Breast Cancer Res Treat 2011, 129:185-190. 10.1007/s10549-011-1433-2, 3405734, 21394499.
24. Karp SE, Tonin PN, Begin LR, Martinez JJ, Zhang JC, Pollak MN, Foulkes WD. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer 1997, 80:435-441. 10.1002/(SICI)1097-0142(19970801)80:3<435::AID-CNCR11>3.0.CO;2-Y, 9241077.
25. Lidereau R, Eisinger F, Champeme MH, Nogues C, Bieche I, Birnbaum D, Pallud C, Jacquemier J, Sobol H. Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer. Cancer Res 2000, 60:1206-1210.
26. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A, Feleppa F, Huschtscha LI, Thorne HJ, , Fox SB, Yan M, French JD, Brown MA, Smyth GK, Visvader JE, Lindeman GJ. kConFab Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 2009, 15:907-913. 10.1038/nm.2000, 19648928, kConFab.
27. Chang S, Wang RH, Akagi K, Kim KA, Martin BK, Cavallone L, , Haines DC, Basik M, Mai P, Poggi E, Isaacs C, Looi LM, Mun KS, Greene MH, Byers SW, Teo SH, Deng CX, Sharan SK. kConFab Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155. Nat Med 2011, 17:1275-1282. 10.1038/nm.2459, 3501198, 21946536, kConFab.
28. Yoon SY, Thong MK, Taib NA, Yip CH, Teo SH. Genetic counseling for patients and families with hereditary breast and ovarian cancer in a developing Asian country: an observational descriptive study. Family Cancer 2011, 10:199-205.